- $83.81bn
- $101.99bn
- £31.38bn
- 70
- 69
- 83
- 88
REG - GlaxoSmithKline PLC - ViiV submits NDA for HIV monthly 2 drug injectable
AnnouncementREG - GlaxoSmithKline PLC - ViiV receives CHMP Positive Opinion for Dovato
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - FDA approves ViiV's two-drug HIV regimen, Dovato
AnnouncementREG - GlaxoSmithKline PLC - Publication of AGM and GM Shareholder Documents
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - GSK reporting changes - product sales and IFRS 16
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - GSK announces further positive data from DREAMM-1
AnnouncementREG - GlaxoSmithKline PLC - Data from GARNET study evaluating dostarlimab
AnnouncementREG - GlaxoSmithKline PLC - GSK Annual Report 2018 on Form 20-F
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement